ArticleMedical physics2019
Technical Note: Imaging dose resulting from optimized procedures with limited-angle intrafractional verification system during stereotactic body radiation therapy lung treatment.
Article in Medical physics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeThe limited-angle intrafractional verification (LIVE) system was developed to track tumor movement during stereotactic body radiation therapy (SBRT). However, the four-dimensional (4D) MV/kV imaging procedure results in additional radiation dose to patients. This study is to quantify imaging radiation dose from optimized MV/kV image acquisition in the LIVE system and to determine if it exceeds the American Association of Physicists in Medicine Task Group Report 180 image dose threshold.
methodsTrueBeam™ platform with a fully integrated system for image guidance was studied. Monte Carlo-simulated kV and MV beams were calibrated and then used as incident sources in an EGSnrc Monte Carlo dose calculation in a CT image-based patient model. In three representative lung SBRT treatments evaluated in this study, tumors were located in the patient's posterior left lung, mid-left lung, and right upper lung. The optimized imaging sequence comprised of arcs ranging from 2 to 7, acquired between adjacent three-dimensional (3D)/IMRT beams, with multiple simultaneous kV (125 kVp) and MV (6 MV) image projections in each arc, for different optimization scenarios. The MV imaging fields were generally confined to the treatment target while kV images were acquired with a normal open field size with a full bow-tie filter.
resultsIn a seven-arc acquisitions case (highest imaging dose scenario), the maximum kV imaging doses to 50% of the tissue volume (D50 from DVHs), for spinal cord, right lung, heart, left lung, and the target, were 0.4, 0.4, 0.6, 0.7, and 1.4 cGy, respectively. The corresponding MV imaging doses were 0.1 cGy to spinal cord, right lung, heart, and left lung, and 11 cGy to target. In contrast, the maximum radiation dose from two cases treated with two Volumetric-Modulated Arc Therapy (VMAT) fields and two-arc image acquisitions is approximately 30% of that of the seven-arc acquisition.
conclusionsWe have evaluated the additional radiation dose resulting from optimized LIVE system MV/kV image acquisitions in two best (least imaging dose) and one worst (highest imaging dose) lung SBRT treatment scenarios. The results show that these MV/kV imaging doses are comparable to those resulting from current imaging procedures used in Image-Guided Radiation Therapy (IGRT) and are within the dose threshold of 5% target dose as recommended by the AAPM TG-180 report.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.